Pioneering Therapies Built on a Natural Immune Regulator
BioAegis is a clinical-stage private company developing therapies for inflammatory diseases.
Our platform is built around plasma gelsolin (pGSN), an abundant human blood protein that regulates the immune response, the body’s first line of defense against both infectious and non-infectious health threats.
Plasma Gelsolin Deficiency: A Hidden Driver of Disease Severity
Inflammation plays a central role in the world’s most challenging diseases and is also associated with aging. Normal levels of plasma gelsolin (pGSN) are rapidly depleted by diverse inflammatory conditions. Restoring gelsolin levels with BioAegis’ proprietary human recombinant form (rhu-pGSN), supercharges immune cells to fight infection and controls inflammation so it does not spread and cause damage. Rhu-pGSN is a non-immunosuppressive treatment for inflammation due to both infectious and non-infectious causes.
Explore the unique advantages powering BioAegis' transformative approach.
REGULATES INFLAMMATION
REGULATES INFLAMMATION
With a uniquely multifaceted mechanism of action, plasma gelsolin not only neutralizes the inflammatory triggers that fuel tissue damage but also restores immune balance. The result is powerful modulation of the inflammatory cascade without suppressing the body’s essential ability to fight infection.
KEY COMPONENT OF IMMUNE FUNCTION
KEY COMPONENT OF IMMUNE FUNCTION
Plasma Gelsolin is a key component of the innate immune system - the first line of defense against threats. This system defends against a wide variety of organisms, boosting the ability of pathogen fighting cells to address infection.
BENIGN SAFETY PROFILE
BENIGN SAFETY PROFILE
BioAegis’ recombinant human plasma gelsolin is identical to the natural human protein. As a result, treatment is not expected to result in serious side effects. In confirmation of this, no serious side effects were identified in animals or four human studies.
NON IMMUNOSUPPRESSIVE
NON IMMUNOSUPPRESSIVE
Most agents which interfere with the inflammatory process work by suppressing the immune response. Plasma gelsolin is unique in that its mechanism is not immunosuppressive.
ACUTE AND CHRONIC DISEASE APPLICATIONS
ACUTE AND CHRONIC DISEASE APPLICATIONS
Multiple disease applications --- $50 billion pipeline market opportunity.
EXTENSIVE IP PORTFOLIO
EXTENSIVE IP PORTFOLIO
Our original IP and know-how were licensed from a consortium of Harvard institutions and other collaborators resulting in more than 40 patents being granted globally to date. BioAegis also benefits from newly filed patents, as well as 12 years of biologics exclusivity in the US beginning at approval of the product and data exclusivity of 11 years in the EU.
“Plasma gelsolin is thought be an important anti-inflammatory protein… Low levels correlating with mortality could be an important biomarker for disease and may suggest a potential therapeutic role for exogenously administered gelsolin.”
“Inflammation has hit the big time. Over the past decade, it has become widely accepted that inflammation is a driving force behind chronic diseases that will kill nearly all of us. Cancer. Diabetes and obesity. Alzheimer’s disease. Atherosclerosis. Here, inflammation wears a grim mask, shedding its redeeming features and making sick people sicker…..”
“Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.”
A Powerful Platform Backed by Partnerships, Patents and Life-Saving Potential
We have built a strong foundation for growth through innovation, strategic partnerships, and market insight. Our expanding patent portfolio secures our core technology, while collaborations with leading research institutions and industry partners accelerate development and validation. With a disciplined approach to execution, we are well positioned to deliver breakthrough therapies that address critical unmet needs.
Patents
>
0
Collaborators
0
+
Market Potential
$
0
B